"I have been impressed with PharmaMar's progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines," Besman said. "PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company's future success as we seek to continue building shareholder value."
DESPUES DE 18 AÑOS CON SOLO TOPOTECAN CON FULL APPROVAL EN EEUU COMO TREATMENT 2a LÍNE SCLC-ES ... LA USFDA ACABA DE APROBAR AL TARLATAMAB CON FULL APPROVAL ... POR LO QUE ES YA EL NEW TREATMENT STÁNDARD EN EEUU . TIENE APROBACIÓNES ACELERADAS EN CANADA , UK, COREA ... Y EN DÍAS PODRÍA ALCANZAR LA APROBACIÓN TAMBIÉN EN CHINA QUE EN JULIO 2025, LA NMPA ACEPTÓ LA SOLICITUD DE REGISTRO (NDA) PARA TARLA OTORGÁNDOLE ADEMAS LA REVISIÓN PRIORITARIA . LA EMA TAMBIÉN LO ESTÁ YA EVALUANDO .
02 enero 2017
PharmaMar Names Besman New Chief Operating Officer .
Dec 31, 2016 .
... Besman's responsibilities will include overseeing the implementation of PharmaMar’s operational infrastructure in the U.S.
"I have been impressed with PharmaMar's progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines," Besman said. "PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company's future success as we seek to continue building shareholder value."
"I have been impressed with PharmaMar's progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines," Besman said. "PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company's future success as we seek to continue building shareholder value."